STALICLA
Samuel Valentini is a bioinformatic software developer at STALICLA since January 2023. Previously, Samuel held the position of PhD Candidate and Research Fellow at Università di Trento from March 2018 to January 2023. Additionally, Samuel gained experience as a Visiting PhD Student at the Barcelona Supercomputing Center from October 2021 to January 2022. Samuel completed a Doctor of Philosophy (PhD) in Bioinformatics at Università di Trento from November 2018 to October 2022, following a Master's degree in Computer Science from September 2015 to December 2017, and a Bachelor's degree in Computer Science from September 2012 to July 2015, both also at Università di Trento.
This person is not in any offices
STALICLA
STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders.STALICLA’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terriblebiomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.STALICLA’s technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The AI/ML engine converges molecular data with human genetic information and non-behavioral clinical signs and symptoms, to define biologically related subgroups and create testable clinical hypotheses related to that biology. The DEPI platform has already completed several successful clinical validations, through the identification and biological validation of two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with their predicted tailored treatment candidates (STP1 and STP2); as well as the blindly and retrospective calling “high” responder patients to previously failed drug candidates with high specificity, sensitivity, and positive predictive value.Further the completion of STP1 Phase 1b in 2022, STP1 will enter clinical Phase 2 in 2023; as well as STP2, a Phase 2 ready asset in licensed in Q4 ’22. Additionally, STALICLA will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb.STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.